Synthesis and Pharmacological Properties of 1-(6-Aminohexylamino)-1-Phenylcyclohexyl Dihydrochloride (IEM-2062) as Compared with Memantine
- Autores: Gmiro V.E.1, Serdyuk S.E.1, Veselkina O.S.2
- 
							Afiliações: 
							- Institute of Experimental Medicine
- ZAO Vertex Pharmaceutical Company
 
- Edição: Volume 53, Nº 1 (2019)
- Páginas: 29-34
- Seção: Article
- URL: https://ogarev-online.ru/0091-150X/article/view/245596
- DOI: https://doi.org/10.1007/s11094-019-01950-z
- ID: 245596
Citar
Resumo
1-(6-Aminohexylamino)-1-phenylcyclohexyl dihydrochloride (IEM-2062) had significantly greater antihypoxic, anticonvulsant, antidepressant, and analgesic activity than memantine and similar antiparkinsonism activity as memantine; it had low toxicity and was safer for use. IEM-2062 produced significant pharmacological effects in the dose range 0.3 – 3 mg/kg.
Palavras-chave
Sobre autores
V. Gmiro
Institute of Experimental Medicine
							Autor responsável pela correspondência
							Email: gmiro2119@gmail.com
				                					                																			                												                	Rússia, 							12 Academician Pavlov Street, St. Petersburg, 197376						
S. Serdyuk
Institute of Experimental Medicine
														Email: gmiro2119@gmail.com
				                					                																			                												                	Rússia, 							12 Academician Pavlov Street, St. Petersburg, 197376						
O. Veselkina
ZAO Vertex Pharmaceutical Company
														Email: gmiro2119@gmail.com
				                					                																			                												                	Rússia, 							27A 24th Line, Vasilevskii Ostrov, St. Petersburg, 199106						
Arquivos suplementares
 
				
			 
						 
						 
						 
						 
					 
				 
  
  
  
  
  Enviar artigo por via de e-mail
			Enviar artigo por via de e-mail  Acesso aberto
		                                Acesso aberto Acesso está concedido
						Acesso está concedido Somente assinantes
		                                		                                        Somente assinantes
		                                					